INBX

Conviction 55HealthcareScan · Mon, Aug 10, 2026

INBX$93.27+5.20%

ResistanceSupportVol 14

Vol MA14 203.65K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Inhibrx Biosciences, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.inhibrx.com ↗

Price93.27

Change+5.20%

Gap+1.51%

Rel volume1.51×

Avg volume223.19K

Avg $ vol19.26M

SMA 2085.55

SMA 5090.94

SMA 20085.28

Price vs 50+2.56%

Price vs 200+9.37%

MA stackbullish

50/200 cross—

Supertrenddown · 95.76

RSI (14)59

MACD hist1.30

MACD crossbull · 3d

Stoch %K / %D96 / 84

ADX (14)13

+DI / −DI21 / 17

RSI divergence—

MACD divergence—

ATR %+5.90%

ADR %5.52%

52w high141.84

52w low21.06

From 52w high-34.24%

Above 52w low+342.88%

New 52w highNo

SqueezeFired

Bollinger width18.42%

%B0.99

Donchian pos94.04%

Donchian high94.27

Donchian low77.51

AVWAP (52w high)107.51

vs AVWAP high-13.25%

AVWAP (52w low)82.06

vs AVWAP low+13.66%

OBV trendFlat

Chaikin MF (20)0.03

Today vs 20d1.51×

Avg vol (14d)203.65K

Avg vol (20d)223.19K

Avg $ vol (20d)19.26M

Market cap—

RS 3m (vs SPY)-34.50%

RS 6m (vs SPY)-5.37%

RS line new highNo

Trend template6/8

Technical rank63.6

1 week+12.75%

1 month+0.28%

3 months-30.58%

6 months+11.15%

1 year+337.07%

YTD+24.29%

P/E-9.29

P/B-61.88

P/S—

P/FCF-10.03

EPS-9.04

Div yield—

ROE665.82%

ROA-76.13%

Debt/Eq-8.32

Current6.46

EV/EBITDA-9.92

Gross margin—

Net margin—

Rev growth550.00%

EPS growth-108.30%

Price target277.50

Target upside212.80%

Analyst ratingBuy

Institutional93.38%

Ent. value1.31B

Revenue0

Net income-33.44M

Gross profit—

Free cash flow-129.82M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out14.67M

Employees110

ListedTue, May 28, 2024

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeC

Conviction55 / 100

Pattern quality—

Tech rank63.6 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance105.10

Support80.36

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in INBX

All disclosures →

No recent disclosed trades by Congress in INBX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in INBX · 5 buys

Insider	Side	Shares	Value	Traded	Filed
MANHARD KIMBERLY Director · Stock Option (right to buy) · 2026-06-03	Grant	15K	$0	2026-06-03	2026-06-04
Kayyem Jon Faiz Director · Stock Option (right to buy) · 2026-06-03	Grant	15K	$0	2026-06-03	2026-06-04
Vuori Kristiina MD Director · Stock Option (right to buy) · 2026-06-03	Grant	15K	$0	2026-06-03	2026-06-04
FORSYTH DOUGLAS Director · Stock Option (right to buy) · 2026-06-03	Grant	15K	$0	2026-06-03	2026-06-04
Matly David President · Stock Option (right to buy) · 2026-04-24	Grant	50K	$0	2026-04-24	2026-04-27

SEC filings

EDGAR filings in INBX · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.